Long-term therapy of severe acne: selection of doses and administration schemes for systemic isotretinoin

Cover Page


Cite item

Full Text

Abstract

The article presents current data on the application of a systemic retinoid, isotretinoin, on the basis of the Lidose system for the treatment of patients with severe forms of acne. It also discusses issues of optimization of the daily dose of isotretinoin taking into consideration long-term clinical efficacy and safety of the therapy. The article presents the results of the authors’ study demonstrating the possibility to select mainly large or small doses of systemic isotretinoin depending on the treatment duration.

About the authors

A. L. Bakulev

Saratov State Medical University named after V.I. Razumovsky Bolshaya

Author for correspondence.
Email: al_ba05@mail.ru
Россия

S. S. Kravchenya

Saratov State Medical University named after V.I. Razumovsky Bolshaya

Email: noemail@neicon.ru
Россия

A. N. Platonova

Saratov State Medical University named after V.I. Razumovsky Bolshaya

Email: noemail@neicon.ru
Россия

I. A. Igonina

Saratov State Medical University named after V.I. Razumovsky Bolshaya

Email: noemail@neicon.ru
Россия

References

  1. Nast A., Dreno B., Bettoli V. et al. European Evidence-based (S3) Guidelines for the Treatment of Acne. JEADV 2012; 26: 1: 1-29.
  2. Goodfield M.J.D., Cox N.H., Bowser A. et al. Advice on the safe introduction and continued use of isotretinoin in acne in the U.K. 2010. Br J Dermatol 2010; 162: 1172-1179.
  3. Strauss J.S., Stranieri A.M. Changes in long-term sebum production from isotretinoin therapy. J Am Acad Dermatol 1982; 6: 751-6.
  4. Shahidullah M., Tham S.N., Goh C.L. Isotretinoin therapy in acne vulgaris: a 10-year retrospective study in Singapore. Int J Dermatol 1994; 33: 60-3.
  5. Stainforth J.M., Layton A.M., Taylor J.P. et al. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol 1993; 129: 297-301.
  6. Zouboulis C.C. The truth behind this undeniable efficacy - recurrence rates and relapse risk factors of acne treatment with oral isotretinoin. Dermatology 2006; 212: 99-100.
  7. Bottomley W.W., Cunliffe W.J. Severe flares of acne following isotretinoin: large closed comedones (macrocomedones) are a risk factor. Acta Derm Venereol 1993; 73-74.
  8. Goulden V., Clark S.M., McGeown C. et al. Treatment of acne with intermittent isotretinoin. Br J Dermatol 1997; 137: 106-8. Литература
  9. Harms M., Masouye I., Radeff B. The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study. Dermatologica 1986; 172: 148-53.
  10. Harms M., Duvanel T., Williamson C. et al. Isotretinoin for acne: should we consider the total cumulative dose. In: Marks R, Plewig G (eds). Acne and Related Disorders. London: Martin Dunitz 1989; 203-6.
  11. Rademaker M. Adverse effects of isotretinoin. A retrospective study of 1743 patients. Australas J Dermatol 2010; 51: 248-53.
  12. Plewig G., Dressel H., Pfleger M. et al. Low dose isotretinoin combined with tretinoin is effective to correct abnormalities of acne. J Dtsch Dermatol Ges 2004; 2: 31-45.
  13. Geissler S.E., Michelsen S., Plewig G. Very low dose isotretinoin is effective in controlling seborrhea. J Dtsch Dermatol Ges 2003; 1: 952-8.
  14. Rademaker M. Isotretion: dose, duration and relapse. What does 30 years of usage tell us? Australas J Dermatol 2013; 54: 157-162.
  15. Colburn W.A., Gibson D.M., Wiens R.E., et al. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 1983; 23(11-12): 534-539.
  16. Hogan D.J., Strand L.M., Lane P.R. Isotretinoin therapy for acne: a populationbased study. CMAJ 1988 Jan 1; 138(1): 47-50.
  17. Cohen B., Evers S., Manske S., et al. Smoking, physical activity and breakfast consumption among secondary school students in a southwestern Ontario community. Can J Public Health 2003; 94(1): 41-44.
  18. Rampersaud G.C., Pereira M.A., Girard B.L., et al. Breakfast habits, nutritional status, body weight, and academic performance in children and adolescents. J Am Diet Assoc 2005; 105(5): 743-60.
  19. Laboratories S.M.B., Brussels, Belgium. Web site. Lidose. Available at: http://www.smblab.be/index.php/formulation/lidose. Accessed July 29, 2013.
  20. Webster G.F., Leyden J.J., Gross J.A. Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study. J Am Acad Dermatol 2013 Aug 13.
  21. Gollnick H., Cunliffe W., Berson D., et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003 Jul; 49(1 Suppl): 1-37.
  22. Tan J., Knezevic S. Improving bioavailability with a novel isotretinoin formulation (isotretinoin-lidose). Skin Therapy Lett. 2013; 18(6). 1-3.
  23. Webster G., Leyden J., Gross J. Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: A randomized, 4-treatment, crossover study. JAAD 2013; 69(5): 762-767.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bakulev A.L., Kravchenya S.S., Platonova A.N., Igonina I.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies